Is cardiorespiratory disease associated with increased susceptibility of SARS-CoV-2 in children?
COVID-19
SARS-CoV-2
asthma
cardiac
child
pediatric lung disease
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
29
07
2021
received:
05
04
2021
accepted:
19
08
2021
pubmed:
3
9
2021
medline:
15
12
2021
entrez:
2
9
2021
Statut:
ppublish
Résumé
There are limited data in pediatric populations evaluating whether chronic cardiorespiratory conditions are associated with increased risk of coronavirus disease 2019 (COVID-19). We aimed to compare the rates of chronic cardiac and respiratory disease in children testing positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2[+]) compared with those testing negative (SARS-CoV-2[-]) at our institution. Prospective cohort with nested case-control study of all children tested by polymerase chain reaction (PCR) for SARS-CoV-2 by nasopharyngeal/oropharyngeal sampling between March and October 2020. Children were identified prospectively via laboratory notification with age and sex-matching of SARS-CoV-2[+] to SARS-CoV-2[-] (1:2). Clinical data were extracted from the electronic medical record. In total, 179 SARS-CoV-2[+] children (44% females, median age 3.5 years, range: 0.1-19.0 years) were matched to 391 SARS-CoV-2[-] children (42% female, median age 3.7 years, range: 0.1-18.3 years). The commonest comorbidities showed similar frequencies in the SARS-CoV-2[+] and [-] groups: asthma (n = 9, 5% vs. n = 17, 4.4%, p = 0.71), congenital heart disease (n = 6, 3.4% vs. n = 7, 1.8%, p = 0.25) and obstructive sleep apnoea (n = 4, 2.2% vs. n = 10, 2.3%, p = 0.82). In the SARS-CoV-2[+] group, the prevalence of symptomatic disease was similar among children with and without cardiorespiratory comorbidities (n = 12, 75% vs. n = 103, 57%, p = 0.35). A high proportion of children hospitalized with SARS-CoV-2 infection had cardiac comorbidities (23.8%). In this single site data set, rates of pre-existing cardiorespiratory disease were similar in SARS-CoV-2[+] and SARS-CoV-2[-] children. Rates of symptomatic infection were similar between children with and without cardiorespiratory comorbidity. High rates of comorbid cardiac disease were observed among hospitalized children with COVID-19 warranting further research to inform vaccine prioritization.
Sections du résumé
BACKGROUND
There are limited data in pediatric populations evaluating whether chronic cardiorespiratory conditions are associated with increased risk of coronavirus disease 2019 (COVID-19). We aimed to compare the rates of chronic cardiac and respiratory disease in children testing positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2[+]) compared with those testing negative (SARS-CoV-2[-]) at our institution.
METHOD
Prospective cohort with nested case-control study of all children tested by polymerase chain reaction (PCR) for SARS-CoV-2 by nasopharyngeal/oropharyngeal sampling between March and October 2020. Children were identified prospectively via laboratory notification with age and sex-matching of SARS-CoV-2[+] to SARS-CoV-2[-] (1:2). Clinical data were extracted from the electronic medical record.
RESULTS
In total, 179 SARS-CoV-2[+] children (44% females, median age 3.5 years, range: 0.1-19.0 years) were matched to 391 SARS-CoV-2[-] children (42% female, median age 3.7 years, range: 0.1-18.3 years). The commonest comorbidities showed similar frequencies in the SARS-CoV-2[+] and [-] groups: asthma (n = 9, 5% vs. n = 17, 4.4%, p = 0.71), congenital heart disease (n = 6, 3.4% vs. n = 7, 1.8%, p = 0.25) and obstructive sleep apnoea (n = 4, 2.2% vs. n = 10, 2.3%, p = 0.82). In the SARS-CoV-2[+] group, the prevalence of symptomatic disease was similar among children with and without cardiorespiratory comorbidities (n = 12, 75% vs. n = 103, 57%, p = 0.35). A high proportion of children hospitalized with SARS-CoV-2 infection had cardiac comorbidities (23.8%).
CONCLUSIONS
In this single site data set, rates of pre-existing cardiorespiratory disease were similar in SARS-CoV-2[+] and SARS-CoV-2[-] children. Rates of symptomatic infection were similar between children with and without cardiorespiratory comorbidity. High rates of comorbid cardiac disease were observed among hospitalized children with COVID-19 warranting further research to inform vaccine prioritization.
Identifiants
pubmed: 34473903
doi: 10.1002/ppul.25642
pmc: PMC8661609
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3664-3668Subventions
Organisme : The Influenza Complications Alert Network Surveillance System
Organisme : Centers of Excellence in Influenza Research and Surveillance - Cross-Center Southern Hemisphere Project
Organisme : Paediatric Active Enhanced Disease Surveillance and Sentinel Travelers and Research Preparedness Platform for Emerging Infectious Disease
Organisme : Murdoch Children's Research Institute
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Pediatr Pulmonol. 2021 Dec;56(12):3664-3668
pubmed: 34473903
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
Clin Infect Dis. 2020 Dec 3;71(9):2469-2479
pubmed: 32392337
J Cyst Fibros. 2020 Nov;19(6):868-871
pubmed: 33183965
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33263054
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
JAMA Netw Open. 2021 Jun 1;4(6):e2111182
pubmed: 34097050
Eur J Pediatr. 2021 Mar;180(3):689-697
pubmed: 32914200
Am J Otolaryngol. 2020 Sep - Oct;41(5):102573
pubmed: 32531620
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
JAMA Pediatr. 2020 Sep 1;174(9):882-889
pubmed: 32320004
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
J Pediatr. 2020 Aug;223:14-19.e2
pubmed: 32407719
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 32978309
Eur J Pediatr. 2020 Jul;179(7):1079-1087
pubmed: 32474800
Lancet Respir Med. 2020 May;8(5):e35-e36
pubmed: 32304639
J Allergy Clin Immunol Pract. 2021 Feb;9(2):684-692.e1
pubmed: 33242628